当前位置: 首页 >> 检索结果
5343. Partnering to deliver sustainable children's surgical care in Kakuma refugee camp.
作者: Neema Kaseje.;Khalid Hassan.;Jesse Muriithi.;John Burton.;Benjamin Weswa.;Kefa Ojwando.;Collins Chirchir.;Stephen Kinara.;David Cunningham.;Stephen Okelo.
来源: Lancet. 2023年401卷10374期328-331页 5344. Life expectancy by county, race, and ethnicity in the USA, 2000-19: a systematic analysis of health disparities.
There are large and persistent disparities in life expectancy among racial-ethnic groups in the USA, but the extent to which these patterns vary geographically on a local scale is not well understood. This analysis estimated life expectancy for five racial-ethnic groups, in 3110 US counties over 20 years, to describe spatial-temporal variations in life expectancy and disparities between racial-ethnic groups.
5347. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
作者: Manali Kamdar.;Scott R Solomon.;Jon Arnason.;Patrick B Johnston.;Bertram Glass.;Veronika Bachanova.;Sami Ibrahimi.;Stephan Mielke.;Pim Mutsaers.;Francisco Hernandez-Ilizaliturri.;Koji Izutsu.;Franck Morschhauser.;Matthew Lunning.;David G Maloney.;Alessandro Crotta.;Sandrine Montheard.;Alessandro Previtali.;Lara Stepan.;Ken Ogasawara.;Timothy Mack.;Jeremy S Abramson.; .
来源: Lancet. 2022年399卷10343期2294-2308页
Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed within 12 months of first-line therapy are at high risk for poor outcomes with current standard of care, platinum-based salvage immunochemotherapy and autologous haematopoietic stem cell transplantation (HSCT). Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has previously demonstrated efficacy and manageable safety in third-line or later LBCL. In this Article, we report a prespecified interim analysis of liso-cel versus standard of care as second-line treatment for primary refractory or early relapsed (within 12 months after response to initial therapy) LBCL.
5348. Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials.
作者: Julio F Fiore.;Charbel El-Kefraoui.;Marc-Aurele Chay.;Philip Nguyen-Powanda.;Uyen Do.;Ghadeer Olleik.;Fateme Rajabiyazdi.;Araz Kouyoumdjian.;Alexa Derksen.;Tara Landry.;Alexandre Amar-Zifkin.;Amy Bergeron.;Agnihotram V Ramanakumar.;Marc Martel.;Lawrence Lee.;Gabriele Baldini.;Liane S Feldman.
来源: Lancet. 2022年399卷10343期2280-2293页
Excessive opioid prescribing after surgery has contributed to the current opioid crisis; however, the value of prescribing opioids at surgical discharge remains uncertain. We aimed to estimate the extent to which opioid prescribing after discharge affects self-reported pain intensity and adverse events in comparison with an opioid-free analgesic regimen.
5349. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
作者: Linda C Giudice.;Sawsan As-Sanie.;Juan C Arjona Ferreira.;Christian M Becker.;Mauricio S Abrao.;Bruce A Lessey.;Eric Brown.;Krzysztof Dynowski.;Krzysztof Wilk.;Yulan Li.;Vandana Mathur.;Qurratul Ann Warsi.;Rachel B Wagman.;Neil P Johnson.
来源: Lancet. 2022年399卷10343期2267-2279页
Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was evaluated for treatment of endometriosis-associated pain.
|